EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT05189509
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Registry
-
NCT05189509
-
- Other papers using this trial's data
- Tenecteplase Plus Butyphthalide for Stroke Within 4.5-6 Hours of Onset (EXIT-BT): a Phase 2 Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05189509. Randomized; single masking; primary purpose treatment. Start 2022-02-11 (actual); primary completion 2022-09-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)
- Condition
- Stroke, Ischemic
- Intervention (Drug)
- TNK-Tissue Plasminogen Activator
- Lead sponsor
- General Hospital of Shenyang Military Region
Record details
- Record id
cardio:ct-nct05189509- Content hash
0d753995d11cf9a07726e7a34dacc59060c7ffc183f42f22834da0de1417fc92